News | August 23, 2011

UltraSPECT Dose NM/PET Reduction Systems Installed at Multiple Sites

August 23, 2011— UltraSPECT of Haifa, Israel, announced the sale of more than 10 of its wide beam reconstruction (WBR) software solutions to nuclear pharmaceutical supplier PCI for placement at customer medical facilities throughout Arizona. PCI is a member of United Pharmacy Partners Inc. (UPPI), a nuclear pharmacy network consortium that recently signed a multi-year distribution agreement for the leasing and/or non-exclusive sales of UltraSPECT’s cardiac and bone imaging applications in the United States.

WBR is an innovative technology addressing current concern about patient radiation exposure. It enhances the performance of gamma cameras and PET scanners to enable a 50 percent reduction in injected dose and/or imaging procedure time with no decrease in image quality and while enhancing image resolution.

WBR’s lower dose requirements offer the benefits of minimizing radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. Higher image resolution provides greater lesion localization, raising diagnostic confidence and precision. For many WBR users, the result is enhanced equipment utilization, revenues, patient satisfaction and referrals.

UltraSPECT’s enhanced WBR can either cut 50 percent of standard radiopharmaceutical dose requirements or reduce imaging scan time to a quarter of what it was before, while maintaining full image quality. The most recent WBR application allows both reduction in dose and scan time. This technology can be utilized with most major manufacturers’ nuclear medicine (NM) and positron emission tomography (PET) systems, as well as all clinical software packages.

Tri-City Cardiology Consultants of Mesa, Ariz., recently acquired the technology through PCI. Commenting on its recent WBR installation, Michelle Smudde, office manager at the cardiology group, said, "WBR technology has been easily accepted by our physicians and technologists. The implementation of the software among our fellow practices went pretty quickly." 

Ridge Smidt, Pharm D., owner of PCI Nuclear Pharmacy, added, “The Tri-City WBR installation demonstrates the power of WBR in reducing patient radiation exposure without sacrificing image quality and diagnostic accuracy. If all our nuclear medicine customers were to adopt the technology and incorporate WBR into their general practice, everyone involved would benefit – patients, physicians, technologists, pharmacies and pharmacy staff.”

For more information: www.ultraspect.com, www.pcinuclear.com

 

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Overlay Init